SLN (Silence Therapeutics) Short Ratio


SLN Silence Therapeutics PLC SLN
45 GF Score
Price $10.33
GF Value $0.13
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SLN
45GF Score
Silence Therapeutics PLC SLN
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $10.33 is trading 7846.2% above its estimated GF Value™ of $0.13. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Short Ratio:
  • GF Value™: $0.13 vs. price of $10.33 (7846.2% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
45GF Score

Get the complete analysis for SLN

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.33
Price
$0.13
GF Value